Mylan says FDA warning for Agila site won't hit financial assumptions
This article was originally published in Scrip
Executive Summary
Mylan does not expect the US FDA's warning letter against Agila Specialties' steriles site to have a material impact on its deal with the Indian firm, with no change anticipated in the targeted timelines for the closure of the acquisition. "Based on what we know today, we continue to expect to close the Agila acquisition in Q4 2013 and do not expect that the matter will have a material impact on our financial assumptions with regard to our combined business," Mylan told Scrip.